Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 × 10(9)/L (50 000/mm(3)) during 4 consecutive weeks, starting in weeks 9 to 12, wa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Bennett, Carolyn M., Rogers, Zora R., Kinnamon, Daniel D., Bussel, James B., Mahoney, Donald H., Abshire, Thomas C., Sawaf, Hadi, Moore, Theodore B., Loh, Mignon L., Glader, Bertil E., McCarthy, Maggie C., Mueller, Brigitta U., Olson, Thomas A., Lorenzana, Adonis N., Mentzer, William C., Buchanan, George R., Feldman, Henry A., Neufeld, Ellis J.
Format: Artigo
Jezik:Inglês
Izdano: The American Society of Hematology 2006
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895391/
https://ncbi.nlm.nih.gov/pubmed/16352811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3518
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki